{"url_path":"/sec/amix/10-k/2026/item-12","section_key":"item-12","section_title":"Item 12 **         **Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-020686-index.html","accession_number":"0001437749-26-020686","cik":"0001617867","ticker":"AMIX","issuer_name":"Autonomix Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-020686-index.html","primary_entity_key":"0001617867","primary_entity_name":"Autonomix Medical, Inc."},"word_count":492,"has_tables":true,"body_markdown":"**Item 12.**         **Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**\n\n \n\nThe following table sets forth information, as of June 1, 2026, regarding beneficial ownership of our common stock by:\n\n \n\n \n\n•\n\neach of our directors;\n\n \n\n \n\n•\n\neach of our named executive officers;\n\n \n\n \n\n•\n\nall directors and executive officers as a group; and\n\n \n\n \n\n•\n\neach person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.\n\n \n\nBeneficial ownership is determined according to the rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared voting or investment power of that security and includes options that are currently exercisable or exercisable within 60 days. Each director or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated, we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have sole investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise noted below, the address for each person or entity listed in the table is c/o Autonomix Medical, Inc., 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.\n\n \n\n \n \n\n**As of June 1, 2026**\n\n \n\n \n \n\n**Shares**\n\n**beneficially**\n\n**owned (1)**\n\n \n \n\n**Percent\nof\nClass**\n\n \n\n**Name of Beneficial Owner**\n\n \n** **\n** **\n** **\n \n** **\n** **\n** **\n\n*Executive officers and directors:*\n\n \n* *\n* *\n* *\n \n* *\n* *\n* *\n\nBrad Hauser\n \n \n-\n \n \n \n-\n \n\nLori Bisson\n\n \n \n3,750\n \n \n \n*\n \n\nDr. Robert Schwartz\n\n \n \n35,765\n \n \n \n*\n \n\nLandy Toth\n\n \n \n101,315\n \n \n \n*\n \n\nWalter Klemp\n\n \n \n150,750\n \n \n \n1.3\n%\n\nJonathan P. Foster\n\n \n \n36,563\n \n \n \n*\n \n\nChris Capelli\n \n \n-\n \n \n \n-\n \n\nTrent Smith\n\n \n \n3,750\n \n \n \n*\n \n\nDavid Robins\n \n \n31,131\n \n \n \n*\n \n\nAll Executive Officers and Directors as a group (9 persons)\n\n \n \n363,024\n \n \n \n3.2\n%\n\n \n \n \n \n \n \n \n \n \n\n \n\n*Less than 1%\n\n \n\n(1)       Consists of shares of common stock and shares underlying options and warrants to purchase common stock that are exercisable or vest within 60 days of June 1, 2026.\n\n \n\n(2)       Includes aportion of 15,600 warrants to purchase shares of the Company’s common stock that was held by Portsmouth Therapeutics, Inc., an entity in which Mr. Robins owns a 33.33% interest.\n\n \n\n15\n\n[Table of Contents](#toc)\n\n \n\n**Securities Authorized for Issuance under Equity Compensation Plans**\n\n \n\nThe following table sets forth information regarding our equity compensation plans at March 31, 2026: \n\n \n\n**Plan category**\n\n \n\n**Number of securities to be**\n\n**issued upon exercise of**\n\n**outstanding options,**\n\n**warrants and rights\n( a )**\n\n \n \n\n**Weighted-average**\n\n**exercise price of**\n\n**outstanding options,**\n\n**warrants and rights\n( b )**\n\n \n \n\n**Number of securities remaining**\n\n**available for future issuance**\n\n**under equity compensation**\n\n**plans (excluding securities**\n\n**reflected in column (a))\n( c )**\n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\nEquity compensation plans approved by security holders (1)\n\n \n \n1,000\n \n \n$\n40.00\n \n \n \n2,270,968\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\nEquity compensation plans not approved by security holders (2)\n\n \n \n16,488\n \n \n$\n26.55\n \n \n \n-\n \n\n \n\n(1) Represents shares of common stock issuable upon exercise of outstanding stock options under our current 2023 Stock Plan.\n\n(2) Consists of shares of common stock issuable upon exercise of outstanding stock options and warrants issued for services."}